Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004093 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00004093 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 36 participants.
The verdict
NCT00004093, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have stage III non-small cell lung cancer.
Interventions
- DRUG Gemcitabine
- DRUG carboplatin
- DRUG paclitaxel
- DRUG vinorelbine
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-08 |
| Est. Completion | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004093
The ClinicalTrials.gov registry entry for NCT00004093 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT00004093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004093 about?
NCT00004093 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the eff...
What is the current status of trial NCT00004093?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1999-08. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00004093?
The interventions under investigation include: Gemcitabine (DRUG), carboplatin (DRUG), paclitaxel (DRUG), vinorelbine (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00004093?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.